Please assess the completion status of the following clinical trial:

Trial Title: A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial.~* Male or female, age above or equal to 18 years at the time of signing informed consent.~For Algeria only: Male or female, age above or equal to 19 years at the time of signing the informed consent.~For Taiwan only: Male or female, age above or equal to 20 years at the time of signing the informed consent.~* Diagnosed with type 2 diabetes mellitus~* HbA1c between 7.0 -10.0% (53-86 mmol/mol) (both inclusive).~Exclusion Criteria:~* - Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an highly effective contraceptive method.~* Family or personal history of multiple endocrine neoplasia type 2 (MEN 2) or medullary thyroid carcinoma (MTC). Family is defined as a first degree relative.~* History or presence of pancreatitis (acute or chronic).~* History of major surgical procedures involving the stomach potentially affecting absorption of trial product (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery).~* Any of the following: myocardial infarction, stroke, hospitalization for unstable angina or transient ischaemic attack within the past 180 days prior to the day of screening.~* Subjects presently classified as being in New York Heart Association (NYHA) Class IV.~* Planned coronary, carotid or peripheral artery revascularisation known on the day of screening.~* Renal impairment measured as estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73 m\^2 as per Chronic Kidney Disease Epidemiology Collaboration formula(CKD-EPI).~* Subjects with alanine aminotransferase (ALT) above 2.5 x upper limit of the normal (ULN).~* Presence or history of malignant neoplasms within the past 5 years prior to the day of screening. Basal and squamous cell skin cancer and any carcinoma in-situ is allowed.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oral semaglutide 3mg (Type: EXPERIMENTAL): Subjects will remain on 3 mg for the entire treatment period (26 weeks)
- Oral semaglutide 7mg (Type: EXPERIMENTAL): Subjects will receive 3 mg for for the first 4 weeks, 7 mg for the remainder of the treatment period
- Oral semaglutide 14mg (Type: EXPERIMENTAL): Subjects will receive 3 mg for the first 4 weeks, 7 mg for the next 4 weeks and 14 mg for the remainder of the treatment period
- Placebo (oral semaglutide) (Type: PLACEBO_COMPARATOR): Subjects will receive placebo tablets for the entire treatment period

Based on this trial design, predict the completion outcome and termination type (if applicable).